- $1.79bn
- $1.87bn
- $109.79m
Brief: UroGen Announces FDA Clearance Of IND Application For Immunotherapy UGN-301 Intravesical Solution
U.S. RESEARCH ROUNDUP- Cepton, Helios Technologies, Marinus Pharmaceuticals
Brief: UroGen Pharma Reports Q4 Loss Per Share Of $1.27
Brief: UroGen Pharma Says Molly Henderson Tendered Her Resignation As CFO Effective March 25
Urogen Pharma rises on securing $100 million loan financing
Brief: Urogen Secures $100 Mln Non-Dilutive Term Loan Financing With Pharmakon Advisors
Brief: Urogen Submits Application Supporting Planned Phase 1 Study Of UGN-301 Intravesical Solution In Recurrent Non-Muscle Invasive Bladder Cancer
Brief: Urogen Announces Start Of Pivotal Single-Arm Phase 3 Trial For UGN-102
Brief: First Patient Dosed In Urogen Pharma’s Home Instillation Study Of UGN-102 In Patients With Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (Lg Ir-Nmibc)
UroGen Pharma drops on Q3 miss
Brief: Urogen Pharma Reports $1.35 Q3 Loss Per Share
Brief: UroGen Pharma Reports Second Quarter 2021 Financial Results
Brief: Urogen Pharma Announces License And Supply Agreement With Neopharm To Pursue Regulatory Approval And Commercialization For Jelmyto® In Israel
Brief: Urogen Pharma Reports Preliminary Jelmyto Sales For Q2
U.S. STOCKS ON THE MOVE-Ramaco Resources, ThredUp, Silvergate
Brief: Urogen Pharma Reports Q1 Results
Brief: Urogen Pharma Reports Q4 And FY20 Financial Results
Brief: Urogen Pharma- Announces $75 Mln Of Non-Dilutive Funding From Rtw Investments
Brief: Urogen Pharma Announces Sponsored Research Agreement With The Johns Hopkins University School Of Medicine To Expand Immuno-Oncology Pipeline